13th Symposium Therapeutic Drug Monitoring (TDM) in Psychiatry and Medical practice
Congress Centrum AlpbachAlpbach, AUSTRIA Visit the Venue to read more
The 13th Symposium "TDM in Psychiatry" wants to deal in particular with topics from the practice of TDM.
The training event from 13 to 15 June 2018 is aimed at all interested physicians and scientists from the university and clinic, as well as at established physicians and experts from clinical laboratories.
All methodological aspects of TDM in daily practice, the interpretation of results as well as pharmacogenetic influences are discussed in lectures and practice-oriented workshops. Participants also have the opportunity to present their own subject-specific works as posters. We look forward to welcoming you to an exciting conference in Alpbach.
Alpbach, surrounded by a magnificent mountain landscape, is located on a sunny plateau south of the Inn Valley, just over an hour's drive from Innsbruck. The village wears awards such as "Most Beautiful Village in Austria" and "Most Beautiful Flower Village in Europe" and, at the same time, due to the outstanding congress infrastructure, it is one of the top destinations of the international convention industry.
For the organizers:
Gerald Zernig (Scientific Director) Medical University of Innsbruck
For payment by bank transfer please request an invoice under: email@example.com and name, affiliation and address, email contact address, phone number and billing address.
Registrations with bank transfer will only be processed and confirmed after receipt of the conference fee in the congress account.
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
For the TDM Symposium, a limited number of rooms in different categories, all within walking distance of the convention center, have been reserved. Reservations are made by Alpbach-Tourismus GmbH for a processing fee of 12, - € per booking.
If you do not want to use this service, please book through your travel agent or preferred online platform.
For the reservation please use the form, which you can download with the link above or below this text.
You can fill in the form online and send it directly by e-mail with the digital signature ("Send" button in the middle of the form above), or print and sign it, fax the signed form or email a scan to the address provided.
Abstracts for poster presentations (in English) please send an email to firstname.lastname@example.org . The following format is mandatory as it seeks to publish the abstracts in Pharmacopsychiatry :
MS Word Document (* .doc, * .docx)
Font Arial 12 pt
Maximum 250 words plus titles and authors
Abstracts are evaluated by the program committee and are to be regarded as accepted only after reconfirmation by email
Deadline for submission of abstracts: 15 February 2018
Example abstract (from TDM Symposium 2016):
TDM of psychotropic drugs in body fluids
Braun D., Stegmann B., Haen E.
Clinical Pharmacology at the Department of Psychiatry and Psychotherapy and at the Department of Pharmacology and Toxicology, University of Regensburg, Germany
In therapeutic drug monitoring (TDM) serum or plasma is an often used biological matrix. Investigations on less invasive body fluids like saliva or urine are an important issue, as there are practical problems with blood testing especially with children.
If saliva would be used in TDM, the saliva to plasma concentration ratio should be constant over a wide plasma concentration range. This correlation is shown for some anticonvulsant drugs like phenytoin and carbamazepine. Other active substances like the psychostimulant methylphenidate and dexamphetamine show highly variable ratios of saliva to plasma concentration, depending on the salivary pH and the plasma protein binding of the drug. In that case saliva samples are useful for qualitative detection of drugs and for assuring compliance, but not for optimization of existing pharmacotherapy by TDM.
Urine is suitable for controlling and testing drug abuse, as many drugs are detectable in it. However, quantification of drugs in urine is problematic. Many factors like the hydration status of the body or the urinary pH influence the concentrations.
Another interesting body fluid for quantification of active substances is cerebrospinal fluid (CSF). Its normally low protein content simplifies sample preparation for HPLC. CSF may also reveal the presence of a psychotropic drug at the site of action. Olanzapine shows a clear-cut correlation between concentrations in serum and in CSF, indicating that serum concentrations of olanzapine reflect those in CSF.
In most instances, serum or plasma is the most appropriate body fluid for TDM.
Contact No.: +43 660 1233321
Contact No.: +43 660 1233321